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1. INTRODUCTION {#cam42256-sec-0005}
===============

Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide, accounting for more than 2.0 million newly diagnosed cancer cases and 1.7 million cancer‐related deaths each year.[1](#cam42256-bib-0001){ref-type="ref"} Evidence from large population‐based studies for these numbers may be delayed in diagnosis.[2](#cam42256-bib-0002){ref-type="ref"}, [3](#cam42256-bib-0003){ref-type="ref"} Although approximately 10 percent of lung cancers in asymptomatic patients are detected on chest radiographs, several studies have suggested that most cancer patients are diagnosed after receiving regular check‐ups with the onset of cancer symptoms.[4](#cam42256-bib-0004){ref-type="ref"}, [5](#cam42256-bib-0005){ref-type="ref"}, [6](#cam42256-bib-0006){ref-type="ref"}, [7](#cam42256-bib-0007){ref-type="ref"} Persistent cough and dyspnea were reported as indicators of lung cancer from studies on the diagnosis of lung cancer.[8](#cam42256-bib-0008){ref-type="ref"}, [9](#cam42256-bib-0009){ref-type="ref"} In addition, patients with lung cancer commonly experience multiple symptoms for many months before seeking health care, including nonspecific systemic symptoms of loss of weight, loss of appetite and fatigue, or direct symptoms and physical signs caused by the primary tumor or intrathoracic or extrathoracic spread such as cough, chest pain, hemoptysis, Horner syndrome, enlarged lymph nodes, subcutaneous nodules, and facial swelling.[10](#cam42256-bib-0010){ref-type="ref"}, [11](#cam42256-bib-0011){ref-type="ref"}, [12](#cam42256-bib-0012){ref-type="ref"} However, low awareness of cancer symptoms may contribute to the delay in seeing a doctor, which leads to the diagnosis of late‐stage disease and poor cancer survival outcomes.[2](#cam42256-bib-0002){ref-type="ref"}, [13](#cam42256-bib-0013){ref-type="ref"} There was a better 5‐year‐survival rate for asymptomatic patients (18%) than for those with symptoms caused by the primary tumor (12%).[12](#cam42256-bib-0012){ref-type="ref"} Additionally, those with nonspecific symptoms had a 5‐year‐survival rate of 6%, and those with symptoms indicating metastatic disease had the worst survival rate, with none alive at 5 years. However, data from the national campaign in England showed that there was a 3.1% increase (*P* \< 0.001) in the proportion of nonsmall cell lung cancer (NSCLC) diagnosed at stage I and a 2.3% increase (*P* \< 0.001) in resections for NSCLC patients after raising public awareness about lung cancer symptoms.[14](#cam42256-bib-0014){ref-type="ref"} The results suggest that a sustained increase in resection surgeries may improve long‐term survival, especially in combination with raising public awareness of cancer symptoms and encouraging people with symptoms to visit the hospital. Although, some studies have shown that the majority of patients with advanced lung cancer experience some symptoms, including lung‐specific (cough, dyspnea, and chest pain) and systemic (appetite loss and fatigue) symptoms.[10](#cam42256-bib-0010){ref-type="ref"}, [11](#cam42256-bib-0011){ref-type="ref"}, [15](#cam42256-bib-0015){ref-type="ref"}, [16](#cam42256-bib-0016){ref-type="ref"} Some of the above symptoms, such as loss of appetite, weight loss, fatigue, fever or flu presentations, increase the risk of a lung cancer diagnosis.[17](#cam42256-bib-0017){ref-type="ref"} However, whether lung cancer symptoms are independently associated with the diagnosis of lung cancer is unknown, especially in terms of the pathological type and stage of the disease at diagnosis.[18](#cam42256-bib-0018){ref-type="ref"}

The present study aimed to examine the symptoms and physical signs of lung cancer patients and determine whether these lung cancer symptoms and physical signs were independently associated with diagnosis; this was a hospital‐based multicenter 10‐year retrospective clinical epidemiological study from 2005 to 2014 focusing on primary lung cancer in mainland China. NSCLC is a major type of lung cancer and accounts for approximately 85% of all lung cancers.[19](#cam42256-bib-0019){ref-type="ref"} Therefore, this study focused on NSCLC.

2. MATERIALS AND METHODS {#cam42256-sec-0006}
========================

2.1. Study design and study sites {#cam42256-sec-0007}
---------------------------------

We conducted a hospital‐based multicenter 10‐year retrospective study of randomly selected pathology or cytology‐confirmed primary lung cancer cases from 2005 to 2014 via a medical chart review. The study was part of the Cancer Screening Program in Urban China (CanSPUC), which was supported by the central government.

The details of the hospital selection and case sampling methods have been described previously.[20](#cam42256-bib-0020){ref-type="ref"}, [21](#cam42256-bib-0021){ref-type="ref"} To ensure that our sample was geographically representative of China, we included eight tertiary hospitals from seven regions, including the North, Northeast, Central, South, East, Northwest, and Southwest, based on the traditional administrative district definitions by the National Bureau of Statistics using convenience sampling; the hospitals were the Shanxi Provincial Cancer Hospital (in Shanxi Province, North China), Liaoning Cancer Hospital (in Liaoning Province, Northeast China), Zhejiang Cancer Hospital (in Zhejiang Province, East China), Anhui Cancer Hospital (in Anhui Province, East China), Hunan Cancer Hospital (in Hunan Province, Central China), Guangxi Cancer Hospital (in Guangxi Autonomous Region, South China), Yunnan Cancer Hospital (in Yunnan Province, Southwest China), and Gansu Provincial Hospital (in Gansu Province, Northwest China).[20](#cam42256-bib-0020){ref-type="ref"}, [21](#cam42256-bib-0021){ref-type="ref"} The selected hospitals provided the medical records of patients with lung cancer diagnosed from 2005 to 2014. In addition, we excluded January and February to decrease any confounding effects for the Spring Festival holiday. During this period, most patients celebrate the Spring Festival and go home to spend the holiday with their families, so there were a small number of patients during this time period, which might be a potential confounding outcomes comparison.

2.2. Data collection {#cam42256-sec-0008}
--------------------

The details of the designed case report form (CRF) and data collection process have also been described previously.[18](#cam42256-bib-0018){ref-type="ref"}, [19](#cam42256-bib-0019){ref-type="ref"} The CRF was designed into an initial questionnaire by experts, and the CRF was revised repeatedly into a formal final questionnaire through several rounds of discussion and presurveys. The CRF was used to collect information on the enrolled patients, including the general information, demographic characteristics, symptoms, physical signs, the Eastern Cooperative Oncology Group (ECOG) performance scale (PS), pathological type, and stage determined by the American Joint Commission on Cancer (AJCC) seventh edition stage for lung cancer). All data were abstracted manually or exported by batch from the medical record system. To improve the data quality, we conducted three levels of organized protocol trainings including the national, provincial, and hospital level for local interviewers, who were clinical doctors or postgraduates with well‐trained health professionals over a period of 2 years in lung cancer, or staffs from department of medical record or cancer prevention with requirements of an educational background of clinical medicine or public health in lung cancer. In the process of data collection, the interviewers firstly screened the medical record in local hospitals and recorded whether to include one case according to the above inclusion criteria into a designed form (including age at diagnosis, gender, date at diagnosis, diagnostic information \[pathological type and clinical stage\], and other essential information). The criteria for excluded cases were indicated and an identity number was assigned for each eligible case, then completed information was extracted. All the variables were double‐entered into computer‐based database (EpiData 3.1) for consistency by two local well‐trained clerks, and then were sent to National Program Office for the missing value confirmation and logic check using coded programs in the SAS software. After several rounds of the above procedure, confirmed data were included for analysis. The following symptoms and physical signs were present before the cancer diagnosis. The symptoms included pain in the waist/shoulder/back, chronic cough, sputum with blood, shortness of breath, chest pain, dyspnea, recurrent bronchitis/pneumonia, hoarseness, amyosthenia, hyponatremia, metastases pain, headache, dizzy, sudden dyskinesia, weight loss, fatigue, fever, and others. The physical signs included neck and supraclavicular lymphadenectasis, lymphadenectasis in other locations, subcutaneous nodules, Horner syndrome, facial swelling, abnormal breath sounds, and others. All information, including age, sex, family history of lung cancer, body mass index (BMI), smoking history, alcohol consumption status, socioeconomic status, education level, symptoms, physical signs, ECOG PS, pathological type of the disease, and disease stage, were collected during the review of the medical charts. This study focused on NSCLC patients, and patients without available information on symptoms, physical signs, pathological type, and stage were excluded.

2.3. Data processing {#cam42256-sec-0009}
--------------------

According to the differences in BMI across the Chinese population, the categories in our study were classified by BMI according to the Chinese adult BMI classification made by the China Obesity Task Force.[22](#cam42256-bib-0022){ref-type="ref"} Namely, patients with BMIs \<18.5 kg/m^2^ were low weight, 18.5‐23.9 kg/m^2^ were normal weight, 24.0‐27.9 kg/m^2^were overweight, and BMI ≥28.0 kg/m^2^ were obese in the present study. According to several economic indictors,[20](#cam42256-bib-0020){ref-type="ref"} the Anhui Province, Yunnan Province, Gansu Province, and Guangxi Autonomous Region were divided into the less‐developed region. The Liaoning, Zhejiang, Hunan, and Shanxi Provinces were divided into the well‐developed region to represent Northeast, North, South, and East China. According to the differences in education level, patients with a primary school education or below were defined as low education, those with a middle school and high school education were defined as middle education, and those with a college degree or above were defined as high education.

2.4. Statistical analysis {#cam42256-sec-0010}
-------------------------

The baseline characteristics are described as frequencies and percentages for categorical variables and as means and standard deviations for continuous variables. Differences in categorical data between patients with and without symptoms and physical signs were compared with the chi‐square test or Fisher\'s exact test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariate unconditional logistic regressions to describe associations between the symptoms and physical signs of lung cancer and age, sex, smoking history, drinking history, BMI, socioeconomic status, education level, disease stage at diagnosis, and pathological type of disease. For all analyses, the statistical software SAS version 9.4 was used. A *P* value \< 0.05 was considered significant.

3. RESULTS {#cam42256-sec-0011}
==========

3.1. Patient characteristics {#cam42256-sec-0012}
----------------------------

A total of 7184 patients diagnosed with lung cancer with disease stage information were surveyed between 2005 and 2014, and a total of 6398 NSCLC patients with available information about their symptoms and physical signs were included in this analysis. Table [1](#cam42256-tbl-0001){ref-type="table"} describes the differences in the demographics of the patients with and without symptoms and physical signs. In our study, 4623 (72.3%) participants were men, and 1775 (27.7%) were women. The mean age for the overall population was 58.4 ± 10.1 years. We found that subjects who had symptoms were more likely to be younger (\<65 years \[71.4%\] and ≥ 65 years \[28.6%\]), to be men (72.3%), and to have been diagnosed with stage III (34.4%) or IV (28.7%) disease than those who did not have symptoms. Additionally, the data suggested that the patients with symptoms were also more likely to have a normal BMI (55.2%), to be smokers (42.6%), to be not consume alcohol (67.3%), and to have a family history of lung cancer (91.6%) than the other populations. As seen in Table [1](#cam42256-tbl-0001){ref-type="table"}, we found that there were significant differences between patients with and without symptoms in relation to age (*P* = 0.0042), sex (*P* \< 0.0001), smoking history (*P* \< 0.0001), drinking history (*P* \< 0.0001), BMI (*P* \< 0.0001), socioeconomic status (*P* = 0.0003), education level (*P* \< 0.0001), pathological type (*P* \< 0.0001), and disease stage (*P* \< 0.0001). Significant differences between patients with and without physical signs were also observed in relation to age (*P* = 0.0050), smoking history (*P* \< 0.0001), drinking history (*P* \< 0.0001), BMI (*P* = 0.0030), socioeconomic status (*P* \< 0.0001), education level (*P* \< 0.0001), pathological type (*P* \< 0.0001), and disease stage (*P* \< 0.0001).

###### 

Demographic characteristics of all included NSCLC patients

  Characteristics                               Symptoms     Physical signs                                                            
  ------------------------------- ------------- ------------ ---------------- -------- ---------- ------------- ------------- -------- ----------
  Age at diagnosis                                                                                                                     
  ＜45                            609 (9.5)     100 (9.4)    509 (9.6)        13.21    0.0042     502 (9.0)     107 (12.7)    12.83    0.0050
  45‐64                           3963 (61.9)   616 (58.0)   3347 (62.7)                          3470 (62.5)   493 (58.5)             
  65‐70                           912 (14.3)    161 (15.1)   751 (14.1)                           797 (14.3)    115 (13.7)             
  ＞70                            914 (14.3)    186 (17.5)   728 (13.6)                           787 (14.2)    127 (15.1)             
  Family history of lung cancer                                                                                                        
  No                              535 (8.3)     96 (9.0)     439 (8.2)        3.99     0.1361     461 (8.3)     74 (8.8)      0.83     0.6599
  Yes                             5859 (91.6)   965 (90.8)   4894 (91.7)                          5091 (91.6)   768 (91.2)             
  Unknown                         4 (0.1)       2 (0.2)      2 (0.1)                              4 (0.1)       0                      
  Body mass index (kg/m^2^)                                                                                                            
  ＜18.5                          538 (8.4)     60 (5.6)     478 (9.0)        46.17    ＜0.0001   457 (8.2)     81 (9.6)      16.04    0.0030
  18.5‐24.0                       3531 (55.2)   559 (52.6)   2972 (55.7)                          3067 (55.2)   464（55.1）            
  24.0‐28.0                       1345 (21.0)   283 (26.6)   1062 (19.9)                          1191 (21.4)   154 (18.3)             
  ≥28.0                           240 (3.8)     58 (5.5)     182 (3.4)                            219 (4.0)     21 (2.5)               
  Unknown                         744 (11.6)    103 (9.7)    641 (12.0)                           622 (11.2)    122 (14.5)             
  Smoking history                                                                                                                      
  Current                         2728 (42.6)   367 (34.5)   2361 (44.2)      68.24    ＜0.0001   2430 (43.7)   298 (35.4)    24.72    ＜0.0001
  Previous                        839 (13.1)    104 (9.8)    735 (13.8)                           711 (12.8)    128 (15.2)             
  Never                           2751 (43.0)   576 (54.2)   2175 (40.8)                          2341 (42.2)   410 (48.7)             
  Unknown                         80 (1.3)      16 (1.5)     64 (1.2)                             74 (1.3)      6 (0.7)                
  Alcohol consumption status                                                                                                           
  Yes                             1763 (27.6)   230 (21.6)   1533 (28.7)      24.20    ＜0.0001   1533 (27.6)   230 (27.3)    39.82    ＜0.0001
  No                              4308 (67.3)   783 (73.7)   3525 (66.1)                          3702 (66.6)   606 (72.0)             
  Unknown                         327 (5.1)     50 (4.7)     277 (5.2)                            321 (5.8)     6 (0.7)                
  Sex                                                                                                                                  
  Male                            4623 (72.3)   689 (64.8)   3934 (73.7)      35.20    ＜0.0001   4030 (72.5)   593 (70.4)    1.62     0.2033
  Female                          1775 (27.7)   374 (35.2)   1401 (26.3)                          1526 (27.5)   249 (29.6)             
  Socioeconomic status                                                                                                                 
  Less                            3223 (50.4)   589 (55.4)   2634 (49.4)      12.92    0.0003     3022 (54.4)   201 (23.9)    272.45   ＜0.0001
  Well                            3175 (49.6)   474 (44.6)   2701 (50.6)                          2534 (45.6)   641 (76.1)             
  Education level                                                                                                                      
  Primary school or below         1696 (26.5)   225 (21.2)   1471 (27.6)      68.11    ＜0.0001   1437 (25.9)   259 (30.8)    9.94     0.0190
  Middle or high school           1765 (27.6)   294 (27.6)   1471 (27.5)                          1544 (27.8)   221 (26.2)             
  College degree or above         390 (6.1)     119 (11.2)   271 (5.1)                            336 (6.0)     54 (6.4)               
  Unknown                         2547 (39.8)   425 (40.0)   2122 (39.8)                          2239 (40.3)   308 (36.6)             
  Pathological type                                                                                                                    
  Adenocarcinoma                  2880 (45.0)   682 (64.1)   2198 (41.2)      192.35   ＜0.0001   2493 (44.9)   387 (46.0)    20.98    ＜0.0001
  Squamous carcinoma              2991 (46.8)   309 (29.1)   2682 (50.3)                          2449 (44.1)   321 (38.1)             
  Others                          527 (8.2)     72 (6.8)     455 (8.5)                            614 (11.0)    134 (15.9)             
  Stage                                                                                                                                
  I                               1272 (19.9)   415 (39.0)   857 (16.1)       325.41   ＜0.0001   1239 (22.3)   33 (3.9)      480.46   ＜0.0001
  IIA                             532 (8.3)     95 (8.9)     437 (8.2)                            507 (9.1)     25 (3.0)               
  IIB                             559 (8.7)     94 (8.9)     465 (8.7)                            517 (9.3)     42 (5.0)               
  IIIA                            1334 (20.9)   186 (17.5)   1148 (21.5)                          1232 (22.2)   102 (12.1)             
  IIIB                            862 (13.5)    87 (8.2)     775 (14.5)                           683 (12.3)    179 (21.3)             
  IV                              1839 (28.7)   186 (17.5)   1653 (31.0)                          1378 (24.8)   461 (54.7)             

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance scale.
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3.2. The outcomes of patients with symptoms and physical signs of lung cancer {#cam42256-sec-0013}
-----------------------------------------------------------------------------

The outcomes of patients with symptoms and physical signs of lung cancer are listed in Figure [1](#cam42256-fig-0001){ref-type="fig"}. The most common initial symptom and physical sign was chronic cough (4156, 65.0%), followed by sputum with blood (2110, 33.0%), chest pain (1146, 17.9%), shortness of breath (1090, 17.0%), neck and supraclavicular lymphadenectasis (629, 9.8%), weight loss (529, 8.3%), metastases pain (378, 5.9%), fatigue (307, 4.8%), fever (272, 4.3%), dyspnea (270, 4.2%), headache (119, 1.9%), and hoarseness (109, 1.7%). Additionally, patients with an ECOG PS of 1 accounted for 21.6% (1380) of the population, those with an ECOG PS of 0 accounted for 14.6% (936 patients) of the population, and the ECOG PS of 59.2% of the patients was unknown. We observed that most patients did not experience any symptoms and physical signs, and the proportion of symptoms seemed to be higher than the proportion of physical signs. The incidence of the symptoms and physical signs of lung cancer were analyzed for the years 2005‐2014, which yielded a line chart, as seen in Figure [2](#cam42256-fig-0002){ref-type="fig"}. The Figure [2](#cam42256-fig-0002){ref-type="fig"} shows that the incidence of the symptoms and physical signs of lung cancer presented a downward tendency year by year.

![The outcomes of symptoms and physical signs](CAM4-8-4055-g001){#cam42256-fig-0001}

![The incidences of symptoms and physical signs analyses in 10 years (2005‐2014)](CAM4-8-4055-g002){#cam42256-fig-0002}

3.3. Association between the selected risk factors and the symptoms and physical signs of NSCLC in China {#cam42256-sec-0014}
--------------------------------------------------------------------------------------------------------

The results of the analysis on the relationship between risk factors and the symptoms and physical signs of lung cancer are listed in Table [2](#cam42256-tbl-0002){ref-type="table"}. In multivariable logistic analyses, having a low body weight (OR = 0.667 \[95% CI, 0.503‐0.886\] for 18.5‐23.9 kg/m^2^, OR = 0.471 \[95% CI, 0.349‐0.635\] for 24.0‐27.9 kg/m^2^, and OR = 0.394 \[95% CI, 0.264‐0.587\] for more than 28.0 kg/m^2^, compared with 18.5 kg/m^2^, respectively), being a smoker (OR = 0.587 \[95% CI, 0.509‐0.677\] for nonsmokers compared with smokers), being a drinker (OR = 0.676 \[95% CI, 0.576‐0.792\] for nondrinkers compared with drinkers), being male (OR = 0.656 \[95% CI, 0.570‐0.754\] for female compared with male), having a low educational level (OR = 0.765 \[95% CI, 0.634‐0.924\] for middle or high school and OR = 0.348 \[95% CI, 0.269‐0.450\] for college degree or above, compared with primary school or below, respectively), and being from more developed regions (OR = 1.274 \[95% CI, 1.116‐1.454\] for well‐developed regions compared with less‐developed regions) was significantly associated with increased the probability of presenting symptoms. Being young (OR = 0.667 \[95% CI, 0.530‐0.838\] for patients with 45‐64 years old and OR = 0.677 \[95% CI, 0.509‐0.901\] for patients with 65‐70 years old compared with patients with less than 45 years old, respectively), being overweight (OR = 0.730 \[95% CI, 0.546‐0.975\] for 24.0 \~ 27.9 kg/m^2^ and OR = 0.541 \[95% CI, 0.326‐0.898\] for more than 28.0 kg/m^2^, compared with 18.5 kg/m^2^, respectively), being a smoker (OR = 1.428 \[95% CI, 1.217‐1.675\] for nonsmokers compared with smokers) and being from well‐developed regions (OR = 3.803 \[95% CI, 3.218‐4.494\] for well‐developed regions compared with less‐developed regions) were associated with a high probability that the participant would develop physical signs. Compared with patients with adenocarcinoma, patients with squamous carcinoma had a higher probability of developing symptoms (OR = 2.885, 95% CI 2.477‐3.359) but not physical signs (OR = 0.844, 95% CI 0.721‐0.989). In addition, patients with stage IIA, stage IIB, stage IIIA, stage IIIB, and stage IV disease were 2.228 (95% CI, 1.733‐2.863), 2.396 (95% CI, 1.864‐3.078), 2.989 (95% CI, 2.461‐3.630), 4.314 (95% CI, 3.357‐5.543), and 4.304 (95% CI, 3.553‐5.213) times more likely to develop symptoms than those with stage I disease, respectively, and 1.851 (95% CI, 1.090‐3.144), 3.049 (95% CI, 1.911‐4.866), 3.108 (95% CI, 2.082‐4.637), 9.837 (95% CI, 6.708‐14.425), and 12.557 (95% CI, 8.749‐18.023) times more likely to develop physical signs than those with stage I disease, respectively. The odds of developing both symptoms and physical signs were higher in patients with advanced‐stage disease than in those with early‐stage disease (*P* \< 0.0001).

###### 

The influencing factors of symptoms and physical signs in the multivariate unconditional logistic regressions

                               Symptoms    Physical signs                                      
  ---------------------------- ----------- ---------------- ---------- -------- -------------- ----------
  Age at diagnosis                                                                             
  ＜45                         Reference                                                       
  45‐64                        1.067       0.847‐1.345      0.5795     0.667    0.530‐0.838    0.0005
  65‐70                        0.916       0.697‐1.205      0.5320     0.677    0.509‐0.901    0.0075
  ＞70                         0.769       0.588‐1.005      0.0547     0.757    0.572‐1.002    0.0519
  Body mass index (kg/m2)                                                                      
  ＜18.5                       Reference                                                       
  18.5 ≤ BMI\<24.0             0.667       0.503‐0.886      0.0051     0.854    0.661‐1.102    0.2248
  24.0 ≤ BMI\<27.9             0.471       0.349‐0.635      ＜0.0001   0.730    0.546‐0.975    0.0310
  ≥28.0                        0.394       0.264‐0.587      ＜0.0001   0.541    0.326‐0.898    0.0174
  Unknown                      0.781       0.556‐1.097      0.1541     1.107    0.815‐1.502    0.5161
  Smoking history                                                                              
  Yes                          Reference                                                       
  Previous                     1.099       0.870‐1.387      0.4290     1.468    1.174‐1.835    0.0008
  Never                        0.587       0.509‐0.677      ＜0.0001   1.428    1.217‐1.675    ＜0.0001
  Unknown                      0.622       0.356‐1.087      0.0955     0.661    0.285‐1.532    0.3347
  Alcohol consumption status                                                                   
  Yes                          Reference                                                       
  No                           0.676       0.576‐0.792      ＜0.0001   1.091    0.927‐1.284    0.2948
  Unknown                      0.831       0.597‐1.158      0.2749     0.125    0.055‐0.283    ＜0.0001
  Sex                                                                                          
  Male                         Reference                                                       
  Female                       0.656       0.570‐0.754      ＜0.0001   1.109    0.946‐1.300    0.2034
  Socioeconomic status                                                                         
  Less                         Reference                                                       
  Well                         1.274       1.116‐1.454      0.0003     3.803    3.218‐4.494    ＜0.0001
  Education level                                                                              
  Primary school or below      Reference                                                       
  Middle or high school        0.765       0.634‐0.924      0.0053     0.794    0.655‐0.963    0.0194
  College degree or above      0.348       0.269‐0.450      ＜0.0001   0.892    0.650‐1.223    0.4774
  Unknown                      0.764       0.641‐0.910      0.0025     0.763    0.639‐0.912    0.0020
  Pathological type                                                                            
  Adenocarcinoma               Reference                                                       
  Squamous carcinoma           2.885       2.477‐3.359      ＜0.0001   0.844    0.721‐0.989    0.0360
  Others                       1.762       1.416‐2.192      ＜0.0001   1.406    1.133‐1.744    0.0019
  Stage                                                                                        
  I                            Reference                                                       
  IIA                          2.228       1.733‐2.863      ＜0.0001   1.851    1.090‐3.144    ＜0.0001
  IIB                          2.396       1.864‐3.078      ＜0.0001   3.049    1.911‐4.866    ＜0.0001
  IIIA                         2.989       2.461‐3.630      ＜0.0001   3.108    2.082‐4.637    ＜0.0001
  IIIB                         4.314       3.357‐5.543      ＜0.0001   9.837    6.708‐14.425   ＜0.0001
  IV                           4.304       3.553‐5.213      ＜0.0001   12.557   8.749‐18.023   ＜0.0001

Abbreviations:CI, confidence interval; OR, odds ratios.
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3.4. Symptoms and physical signs of lung cancer in the distribution of risk factors for NSCLC in China {#cam42256-sec-0015}
------------------------------------------------------------------------------------------------------

The detailed symptoms and physical signs of lung cancer in the distribution of pathological type and disease stage are listed in Tables [3](#cam42256-tbl-0003){ref-type="table"} and [4](#cam42256-tbl-0004){ref-type="table"}, respectively. The data showed that patients with chronic cough (*P* \< 0.0001), sputum with blood (*P* \< 0.0001), hoarseness (*P* = 0.0071), weight loss (*P* = 0.0104), fatigue (*P* = 0.0243), and fever (*P* = 0.0007) were more likely to have squamous carcinoma than nonsquamous carcinoma. While the symptoms of metastases pain (*P* \< 0.0001), dizziness (*P* = 0.0472), and neck and supraclavicular lymphadenectasis (*P* = 0.0006) were more likely to occur in patients with nonsquamous carcinoma than patients with other carcinomas. Additionally, patients with chronic cough were significantly more likely to have stage III disease (*P* \< 0.0001) than diseases of other stages. Patients with stage IV disease had a higher percentage of chest pain (*P* \< 0.0001), shortness breath (*P* \< 0.0001), dyspnea (*P* = 0.0003), metastases pain (*P* \< 0.0001), weight loss (*P* \< 0.0001), fatigue (*P* \< 0.0001), neck and supraclavicular lymphadenectasis (*P* \< 0.0001), lymphadenectasis in other locations (*P* \< 0.0001), subcutaneous nodules (*P* \< 0.0001), facial swelling (*P* = 0.0187), and abnormal breath sounds (*P* \< 0.0001) than patients with disease of other stages. Additionally, patients with early‐stage disease had a better ECOG PS in than those with advanced‐stage disease.

###### 

The distributions symptoms and physical signs in different pathological type

                                              Total         Squamous carcinoma   Adenocarcinoma   Others       *χ* ^2^   *P* value   Nonsquamous carcinoma   Squamous vs Nonsquamous*χ* ^2^   Squamous vs Nonsquamous*P* value
  ------------------------------------------- ------------- -------------------- ---------------- ------------ --------- ----------- ----------------------- -------------------------------- ----------------------------------
  Symptoms                                                                                                                                                                                    
  Pain in waist/shoulder/back                 46 (0.7)      13 (0.5)             27 (0.9)         6 (0.8)      4.42      0.1098      33 (0.9)                4.27                             0.0389
  Chronic cough                               4156 (65.0)   2100 (75.8)          1573 (54.6)      483 (64.6)   278.69    ＜0.0001    2056 (56.7)             252.84                           ＜0.0001
  Sputum with blood                           2110 (33.0)   1208 (43.6)          673 (23.4)       229 (30.6)   263.89    ＜0.0001    902 (24.9)              249.78                           ＜0.0001
  Short breath                                1090 (17.0)   449 (16.2)           512 (17.8)       129 (17.2)   2.48      0.2889      641 (17.7)              2.36                             0.1241
  Chest pain                                  1146 (17.9)   484 (17.5)           526 (18.3)       136 (18.2)   0.64      0.7251      662 (18.2)              0.64                             0.4237
  Dyspnea                                     270 (4.2)     134 (4.8)            111 (3.9)        25 (3.3)     4.99      0.0824      136 (3.7)               4.61                             0.0318
  Recurrent bronchitis/pneumonia              14 (0.2)      8 (0.3)              3 (0.1)          3 (0.4)      3.49      0.1744      6 (0.2)                 1.10                             0.2952
  Hoarseness                                  109 (1.7)     61 (2.2)             31 (1.1)         17 (2.3)     12.32     0.0021      48 (1.3)                7.25                             0.0071
  Amyosthenia                                 12 (0.2)      5 (0.2)              4 (0.1)          3 (0.4)      2.19      0.3340      7 (0.2)                 0.01                             0.9093
  Hyponatremia                                1 (0.0)       0                    1 (0.0)          0            1.22      0.5429      1 (0.0)                 0.76                             0.3822
  Metastases pain                             378 (5.9)     121 (4.4)            206 (7.2)        51 (6.8)     20.96     ＜0.0001    257 (7.1)               20.84                            ＜0.0001
  Headache                                    119 (1.9)     42 (1.5)             56 (1.9)         21 (2.8)     5.58      0.0613      77 (2.1)                3.16                             0.0754
  Dizzy                                       96 (1.5)      32 (1.2)             44 (1.5)         20 (2.7)     9.22      0.0100      64 (1.8)                3.94                             0.0472
  Sudden dyskinesia                           46 (0.7)      17 (0.6)             22 (0.8)         7 (0.9)      1.00      0.6053      29 (0.8)                0.76                             0.3839
  Weight loss                                 529 (8.3)     257 (9.3)            203 (7.0)        69 (9.2)     10.27     0.0059      272 (7.5)               6.57                             0.0104
  Fatigue                                     307 (4.8)     152 (5.5)            118 (4.1)        37 (4.9)     6.01      0.0494      155 (4.3)               5.08                             0.0243
  Fever                                       272 (4.3)     145 (5.2)            97 (3.4)         30 (4.0)     12.21     0.0022      127 (3.5)               11.60                            0.0007
  Others                                      80 (1.3)      27 (1.0)             41 (1.4)         12 (1.6)     3.16      0.2056      53 (1.5)                3.01                             0.0829
  Physical signs                                                                                                                                                                              
  Neck and supraclavicular lymphadenectasis   629 (9.8)     232 (8.4)            294 (10.2)       103 (13.8)   20.18     ＜0.0001    397 (10.9)              11.68                            0.0006
  Other location lymphadenectasis             47 (0.7)      24 (0.9)             16 (0.6)         7 (0.9)      2.34      0.3101      23 (0.6)                1.16                             0.2806
  Subcutaneous nodule                         23 (0.4)      8 (0.3)              8 (0.3)          7 (0.9)      7.86      0.0196      15 (0.4)                0.68                             0.4092
  Horner syndrome                             1 (0.0)       0                    1 (0.0)          0            1.22      0.5429      1 (0.03)                0.76                             0.3822
  Facial swelling                             14 (0.2)      9 (0.3)              1 (0.0)          4 (0.5)      9.32      0.0095      5 (0.1)                 2.52                             0.1125
  Abnormal breath sounds                      97 (1.5)      41 (1.5)             43 (1.5)         13 (1.7)     0.28      0.8690      56 (1.5)                0.04                             0.8371
  Others                                      51 (0.8)      16 (0.6)             30 (1.0)         5 (0.7)      4.02      0.1338      35(1.0)                 2.98                             0.0845
  ECOG PS                                                                                                                                                                                     
  0                                           936 (14.6)    372 (13.4)           477 (165)        87 (11.7)    23.86     0.0024      564 (15.6)              12.21                            0.0159
  1                                           1380 (21.6)   600 (21.7)           613 (21.3)       167 (22.3)                         780 (21.5)                                               
  2                                           239 (3.7)     123 (4.5)            92 (3.2)         24 (3.2)                           116 (3.2)                                                
  ≥3                                          53 (0.8)      20 (0.7)             26 (0.9)         7 (0.9)                            33 (0.9)                                                 
  Unknown                                     3790 (59.2)   1655 (59.7)          1672 (58.1)      463 (61.9)                         2135 (58.8)                                              

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance scale.
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###### 

The distributions symptoms and physical signs in different stages

                                              Stage I      Stage II     Stage III     Stage IV      *χ* ^2^   *P* value   Stage I‐III   Stage I‐III vs IV *χ* ^2^   I‐III vs IV*P* value
  ------------------------------------------- ------------ ------------ ------------- ------------- --------- ----------- ------------- --------------------------- ----------------------
  Symptoms                                                                                                                                                          
  Pain in waist/shoulder/back                 6 (0.5)      7 (0.6)      9 (0.4)       24 (1.3)      12.97     0.0047      22 (0.5)      12.42                       0.0004
  Chronic cough                               652 (51.3)   731 (67.0)   1599 (72.8)   1174 (63.8)   167.44    ＜0.0001    2982 (65.4)   1.42                        0.2336
  Sputum with blood                           360 (28.3)   410 (37.6)   844 (38.4)    496 (27.0)    82.63     ＜0.0001    1614 (35.4)   42.15                       ＜0.0001
  Short breath                                133 (10.5)   149 (13.7)   376 (17.1)    432 (23.5)    102       ＜0.0001    658 (14.4)    76.07                       ＜0.0001
  Chest pain                                  147 (11.6)   162 (14.8)   375 (17.1)    462 (25.1)    107.97    ＜0.0001    684 (15)      91.26                       ＜0.0001
  Dyspnea                                     25 (2.0)     29 (2.7)     112 (5.1)     104 (5.7)     36.16     ＜0.0001    166 (3.6)     13.15                       0.0003
  Recurrent bronchitis/pneumonia              0            3 (0.3)      6 (0.3)       5 (0.3)       3.48      0.3231      9 (0.2)       0.33                        0.5640
  Hoarseness                                  3 (0.2)      6 (0.5)      46 (2.1)      54 (2.9)      43.73     ＜0.0001    55 (1.2)      23.42                       ＜0.0001
  Amyosthenia                                 0            2 (0.2)      3 (0.1)       7 (0.4)       6.36      0.0954      5 (0.1)       5.14                        0.0234
  Hyponatremia                                0            0            0             1 (0.1)       2.48      0.4790      0             2.48                        0.1153
  Metastases pain                             13 (1)       37 (3.4)     91 (4.1)      237 (12.9)    240.5     ＜0.0001    141 (3.1)     226.14                      ＜0.0001
  Headache                                    4 (0.3)      6 (0.5)      19 (0.9)      90 (4.9)      131.55    ＜0.0001    29 (0.6)      130.15                      ＜0.0001
  Dizzy                                       10 (0.8)     3 (0.3)      19 (0.9)      64 (3.5)      70.24     ＜0.0001    32 (0.7)      68.44                       ＜0.0001
  Sudden dyskinesia                           1 (0.1)      1 (0.1)      2 (0.1)       42 (2.3)      88.54     ＜0.0001    4 (0.1)       88.54                       ＜0.0001
  Weight loss                                 28 (2.2)     61 (5.6)     181 (8.2)     259 (14.1)    154.04    ＜0.0001    270 (5.9)     115.08                      ＜0.0001
  Fatigue                                     27 (2.1)     30 (2.7)     91 (4.1)      159 (8.6)     91.62     ＜0.0001    148 (3.2)     83.64                       ＜0.0001
  Fever                                       39 (3.1)     44 (4)       114 (5.2)     75 (4.1)      9.42      0.0242      197 (4.3)     0.19                        0.6631
  Others                                      14 (1.1)     15 (1.4)     19 (0.9)      32 (1.7）     6.58      0.0866      48 (1.1)      5.01                        0.0252
  Physical signs                                                                                                                                                    
  Neck and supraclavicular lymphadenectasis   15 (1.2)     43 (3.9)     220 (10.0)    351 (19.1)    327.9     ＜0.0001    278 (6.1)     249.39                      ＜0.0001
  Other location lymphadenectasis             0            2 (0.2)      15 (0.7)      30 (1.6)      34.32     ＜0.0001    17 (0.4)      28.46                       ＜0.0001
  Subcutaneous nodule                         2 (0.2)      1 (0.1)      1 (0.05)      19 (1.0)      32.98     ＜0.0001    4 (0.1)       32.70                       ＜0.0001
  Horner syndrome                             0            0            0             1 (0.1)       2.48      0.4790      0             2.48                        0.1153
  Facial swelling                             0            1 (0.1)      5 (0.2)       8 (0.4)       7.54      0.0565      6 (0.1)       5.53                        0.0187
  Abnormal breath sounds                      8 (0.6)      13 (1.2)     26 (1.2)      50 (2.7)      26.91     ＜0.0001    47 (1.0)      25.01                       ＜0.0001
  Others                                      8 (0.6)      7 (0.6)      20 (0.9)      16 (0.9)      1.27      0.7361      35 (0.8)      0.17                        0.6770
  ECOG PS                                                                                                                                                           
  0                                           284 (22.3)   236 (21.6)   349 (15.9)    67 (3.7)      536.48    ＜0.0001    869 (19.0)    441.38                      ＜0.0001
  1                                           190 (14.9)   185 (17.0)   540 (24.6)    465 (25.3)                          915 (20.1)                                
  2                                           6 (0.5)      10 (0.9)     66 (3.0)      157 (8.5)                           82 (1.8)                                  
  ≥3                                          1 (0.1)      2 (0.2)      11 (0.5)      39 (2.1)                            14 (0.3)                                  
  Unknown                                     791 (62.2)   658 (60.3)   1230 (56.0)   1111 (60.4)                         2679 (58.8)                               

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance scale.
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4. DISCUSSION {#cam42256-sec-0016}
=============

In this hospital‐based multicenter 10 years (2005 to 2014) retrospective clinical epidemiological study for primary lung cancer in mainland China, 6398 NSCLC patients were included to explicitly provide quantitative information about their symptoms and physical signs; this study included Chinese NSCLC patients to determine whether any relationships existed between the pathological type and disease stage the presence of lung cancer symptoms.

This analysis showed that the most common symptoms and physical signs of lung cancer were chronic cough (65.0%), sputum with blood (33.0%), chest pain (17.9%), shortness of breath (17.0%), neck and supraclavicular lymphadenectasis (9.8%), weight loss (8.3%), metastases pain (5.9%), fatigue (4.8%), fever (4.3%), and dyspnea (4.2%). Early studies reported that 60%‐70% of the patients ultimately diagnosed with pulmonary cancer presented with one or more local symptoms (cough, dyspnea, or chest pain), and 41% had general symptoms (fever, weight loss, or tiredness).[10](#cam42256-bib-0010){ref-type="ref"} An English study reported similar results that the most common symptoms were cough (56.2%), fatigue or tiredness (45.1%), breathlessness (41.2%), chest/shoulder pain (35.3%), and coughing up blood (21.6%).[23](#cam42256-bib-0023){ref-type="ref"} Although the incidence of general symptoms was relatively low in our study, we found that, in keeping with the above studies, the local symptoms of chronic cough, sputum with blood, and chest pain were the main symptoms for lung cancer patients. These findings indicated that the above symptoms might be signs of lung cancer.

An important advantage of this study is the information on the relationships between the symptoms and physical signs of lung cancer and the pathological type and disease stage of NSCLC. A previous study suggested that some symptoms, such as loss of appetite, weight loss, fatigue, and fever/flu presentations, were associated with a high‐lung cancer risk.[17](#cam42256-bib-0017){ref-type="ref"} Furthermore, some of the presented symptoms, such as jaundice, are likely to represent advanced colorectal cancer.[24](#cam42256-bib-0024){ref-type="ref"} A study based on the general population indicated that the incidences of these symptoms were not associated with disease stage.[25](#cam42256-bib-0025){ref-type="ref"} However, few studies have reported the relationship between the symptoms and physical signs of lung cancer and the stage of cancer, particularly for lung cancer. In our study, the incidence of symptoms and physical signs was higher in patients with advanced‐stage disease than in those with early‐stage disease; the odds of patients with stage IIA, stage IIB, stage IIIA, stage IIIB, and stage IV disease presenting symptoms were 2.228 (95% CI, 1.733‐2.863), 2.396 (95% CI, 1.864‐3.078), 2.989 (95% CI, 2.461‐3.630), 4.314 (95% CI, 3.357‐5.543), and 4.304 (95% CI, 3.553‐5.213) times the odds of those with stage I disease, respectively, and the odds of these patients presenting physical signs were 1.851 (95% CI, 1.090‐3.144), 3.049 (95% CI, 1.911‐4.866), 3.108 (95% CI, 2.082‐4.637), 9.837 (95% CI, 6.708‐14.425), and 12.557 (95% CI, 8.749‐18.023) times the odds of those with stage I disease, respectively. These results suggested that there are significant associations between the symptoms and physical signs of lung cancer and disease stage; the more advanced the disease stage, the more likely that symptoms and physical signs are present. Patients were perhaps more likely to have advance‐stage disease if they did experience symptoms or physical signs. One explanation for these findings is that most patients with lung cancer are asymptomatic or the disease is left undetected in its early stage.[14](#cam42256-bib-0014){ref-type="ref"} Another explanation is that the low awareness of cancer symptoms may contribute to delays in seeing a doctor, which leads to the diagnoses of late‐stage disease. Thus, raising public awareness of the symptoms and physical signs of cancer and encouraging people with those indicators to visit hospitals is necessary to achieve favorable clinical outcomes. Few studies have reported whether associations exist between the symptoms and physical signs and the pathological characteristics of lung cancer. In our analysis, squamous carcinoma significantly increased the risk of developing symptoms, but not physical signs (OR = 0.844, 95% CI 0.721‐0.989) compared with adenocarcinoma (OR = 2.885, 95% CI 2.477‐3.359). Additionally, patients with squamous carcinoma were perhaps less likely to present symptoms of chronic cough, sputum with blood, hoarseness, and fever than patients with other carcinomas. This may be because squamous cell lung cancer is a common central disease, which leads to lung‐specific symptoms. We look forward to further prospective cohort studies to explore the results.

Notably, the incidence of the symptoms and physical signs of lung cancer presented a downward tendency year by year. Studies have verified that surgical resection remains a major intervention that can improve long‐term survival for patients with early‐stage lung cancer,[23](#cam42256-bib-0023){ref-type="ref"}, [26](#cam42256-bib-0026){ref-type="ref"} and evidence has indicated that high resection rates were associated with a reduced risk of death in a population‐based study.[27](#cam42256-bib-0027){ref-type="ref"} There was a 3.1% increase (*P* \< 0.001) in the proportion of NSCLC diagnosed at stage I and a 2.3% increase (*P* \< 0.001) in the number of resections for NSCLC after raising public awareness of lung cancer symptoms in an English study.[14](#cam42256-bib-0014){ref-type="ref"} Our results indicate that a higher number of people were diagnosed with NSCLC after undergoing a health examination than only relying on the onset of symptoms year by year. Unfortunately, most patients were still diagnosed at relatively advanced stages (stage III or IV), and nearly 30% of patients were stage IV.

In the previous findings reported in other studies,[25](#cam42256-bib-0025){ref-type="ref"}, [28](#cam42256-bib-0028){ref-type="ref"} women generally reported more symptoms than men. However, in our study, we observed that men were more likely to report symptoms than women. The reason for this result might be that more than 70% of the participants were male, which led to an opposite result. Moreover, in multivariable logistic analyses, having a low body weight, being a smoker and being a drinker were significantly associated with a high probability of developing symptoms. Being young, having a low body weight and being a smoker were associated with a high probability that the participants had physical signs.

In this study, a low education level was found to be associated with a high incidence of the symptoms and physical signs of lung cancer. Patients with advanced‐stage disease were more likely to experience symptoms and physical signs than patients with early‐stage disease. There is evidence that a low educational level was associated with a high risk of being diagnosed with advanced stage lung cancer. Patients with a high education level were less likely to have stage IV lung cancer than those in the illiterate group (OR = 0.52, 0.63, 0.71, and 0.64 for the primary school, middle school, high school, college degree, or above subgroups, respectively).[20](#cam42256-bib-0020){ref-type="ref"} The findings suggest that patients in the most socioeconomically deprived areas might be correlated with a higher risk of advanced‐stage lung cancer, and a high educational level might be associated with a low risk of being diagnosed with advanced‐stage disease for both men and women. In addition, patients with a low educational level or low income were found to be less likely to seek medical advice or undergo treatment for the onset of symptoms than patients with a high education level or high income.[29](#cam42256-bib-0029){ref-type="ref"} One explanation is that patients with a low level of education also have a low awareness of the cancer symptoms, which leads to delays in seeing a doctor and contributes to the late stage at diagnosis. Another possible explanatory factor, which is in line with the report from India, is that financial constraint was reported as the main reason for not promptly seeking help, even for patients who suspected cancer.[30](#cam42256-bib-0030){ref-type="ref"} Interestingly, we found that patients from high‐income regions were likely to report symptoms, but not physical signs. Perhaps patients with high incomes have financial support and are thus likely to seek help promptly when they develop symptoms.

There are some limitations in our study that should be considered when interpreting our results. First, we used hospital‐based data, and the patients from the leading public cancer hospital of each province may not represent the entire population of that area. The data were collected with surveys rather than with random probability sampling, which could have made the sample less representative. Second, all included participants were diagnosed with lung cancer, and thus, there is no comparison between NSCLC patients and controls. Third, patients without available information about their symptoms, physical signs, pathological subtype, and disease stage were excluded from this analysis, which inevitably led to bias.

In summary, the symptoms and physical signs of lung cancer were associated with the pathological and clinical stage of NSCLC at diagnosis. Patients were perhaps likely to be diagnosed with advanced‐stage disease when they experienced symptoms or physical signs, and patients with squamous carcinoma were more likely to develop symptoms, but not physical signs, than patients with adenocarcinoma. Further prospective cohort studies are needed to explore these results.
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